{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:53:42Z","timestamp":1790949222183,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T00:00:00Z","timestamp":1509062400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s40265-017-0831-0","type":"journal-article","created":{"date-parts":[[2017,10,27]],"date-time":"2017-10-27T09:23:49Z","timestamp":1509096229000},"page":"1857-1864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Deutetrabenazine: A Review in Chorea Associated with Huntington\u2019s Disease"],"prefix":"10.1007","volume":"77","author":[{"given":"Young-A","family":"Heo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley J.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,27]]},"reference":[{"issue":"1","key":"831_CR1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","volume":"77","author":"EM Coppen","year":"2017","unstructured":"Coppen EM, Roos RA. Current pharmacological approaches to reduce chorea in Huntington\u2019s disease. Drugs. 2017;77(1):29\u201346.","journal-title":"Drugs."},{"issue":"11","key":"831_CR2","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/mds.25996","volume":"29","author":"J Jankovic","year":"2014","unstructured":"Jankovic J, Roos RA. Chorea associated with Huntington\u2019s disease: to treat or not to treat? Mov Disord. 2014;29(11):1414\u20138.","journal-title":"Mov Disord."},{"issue":"6","key":"831_CR3","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","volume":"79","author":"MJ Armstrong","year":"2012","unstructured":"Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012;79(6):597\u2013603.","journal-title":"Neurology."},{"issue":"4","key":"831_CR4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11910-017-0739-9","volume":"17","author":"KJ Wyant","year":"2017","unstructured":"Wyant KJ, Ridder AJ, Dayalu P. Huntington\u2019s disease-update on treatments. Curr Neurol Neurosci Rep. 2017;17(4):33.","journal-title":"Curr Neurol Neurosci Rep."},{"key":"831_CR5","unstructured":"Anderson KE, Iyer R, Schilling T, et al. Demographics, clinical characteristics, and treatment patterns of Huntington disease patients taking tetrabenazine for chorea: findings from three different data sources In: The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd annual international meeting; 2017."},{"issue":"8","key":"831_CR6","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/mds.25500","volume":"28","author":"R Reilmann","year":"2013","unstructured":"Reilmann R. Pharmacological treatment of chorea in Huntington\u2019s disease-good clinical practice versus evidence-based guideline. Mov Disord. 2013;28(8):1030\u20133.","journal-title":"Mov Disord."},{"issue":"12","key":"831_CR7","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/jamaneurol.2016.3916","volume":"73","author":"R Reilmann","year":"2016","unstructured":"Reilmann R. Deutetrabenazine-not a revolution but welcome evolution for treating chorea in Huntington disease. JAMA Neurol. 2016;73(12):1404\u20136.","journal-title":"JAMA Neurol."},{"issue":"1","key":"831_CR8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2016.8011","volume":"316","author":"MD Geschwind","year":"2016","unstructured":"Geschwind MD, Paras N. Deutetrabenazine for treatment of chorea in Huntington disease. JAMA. 2016;316(1):33\u20135.","journal-title":"JAMA."},{"issue":"10","key":"831_CR9","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1517\/13543776.2014.943184","volume":"24","author":"GS Timmins","year":"2014","unstructured":"Timmins GS. Deuterated drugs: where are we now? Expert Opin Ther Pat. 2014;24(10):1067\u201375.","journal-title":"Expert Opin Ther Pat."},{"key":"831_CR10","unstructured":"Teva Pharmaceuticals USA Inc. AUSTEDO\u2122 (deutetrabenazine): US prescribing information. 2017. http:\/\/www.fda.gov . Accessed 30 Aug 2017."},{"key":"831_CR11","doi-asserted-by":"crossref","unstructured":"Stamler D, Offman E, Bradbury M, et al. A randomized double-blind placebo- and positive-controlled crossover study to evaluate the effects of single doses of SD-809 (deutetrabenazine) and tetrabenazine on the corrected QT interval [abstract no. P2.347]. Neurology. 2016;86(16 Suppl.).","DOI":"10.1212\/WNL.86.16_supplement.P2.347"},{"key":"831_CR12","unstructured":"Donna SC, Levi M, Rabinovich-Guilatt L, et al. Cardiovascular safety assessment of deutetrabenazine in healthy volunteers and implications for patients with Huntington disease or tardive dyskinesia In: Psych Congress; 2017."},{"key":"831_CR13","doi-asserted-by":"crossref","unstructured":"Stamlen D, Bradbury M, De Boer L, et al. A relative bioavailability study of three dose strengths and four dose levels of SD-809, a potential treatment for movement disorders [abstract no. P1.054]. Neurology. 2016;86(16 Suppl.).","DOI":"10.1212\/WNL.86.16_supplement.P1.054"},{"issue":"Suppl. 2","key":"831_CR14","first-page":"S271","volume":"28","author":"DA Stamler","year":"2013","unstructured":"Stamler DA, Brown F, Bradbury M. The pharmacokinetics of extended release SD-809, a deuterium-substituted analogue of tetrabenazine [abstract no. 765]. Mov Disord. 2013;28(Suppl. 2):S271\u20132.","journal-title":"Mov Disord."},{"key":"831_CR15","unstructured":"Lundbeck Inc. XENAZINE\u00ae (tetrabenazine): US prescribing information. 2017. http:\/\/www.fda.gov . Accessed 17 July 2017."},{"issue":"1","key":"831_CR16","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.8655","volume":"316","author":"S Frank","year":"2016","unstructured":"Frank S, Testa CM, Stamler D, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316(1):40\u201350.","journal-title":"JAMA."},{"issue":"8","key":"831_CR17","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamaneurol.2017.1352","volume":"74","author":"S Frank","year":"2017","unstructured":"Frank S, Stamler D, Kayson E, et al. Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. JAMA Neurol. 2017;74(8):977\u201382.","journal-title":"JAMA Neurol."},{"key":"831_CR18","unstructured":"US National Institutes of Health. ClinicalTrials.gov [identifier NCT01897896]. 2017. https:\/\/www.clinicaltrials.gov\/ . Accessed 7 July 2017."},{"key":"831_CR19","unstructured":"Frank S, Vaughan C, Stamler D, et al. The long-term safety of deutetrabenazine for chorea in Huntington disease: a preliminary analysis [abstract no. 468]. Mov Disord. 2017;32 (Suppl 2)."},{"key":"831_CR20","unstructured":"Sung V, Claassen D, Edmondson MC, et al. Comparable neuropsychiatric safety observed with deutetrabenazine treatment and placebo in patients with Huntington disease (FIRST-HD). In: American Psychiatric Association Annual Meeting. 2016."},{"key":"831_CR21","doi-asserted-by":"publisher","unstructured":"Claassen DO, Carroll B, De Boer LM, et al. Indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease. J Clin Mov Disord. 2017. doi: 10.1186\/s40734-017-0051-5","DOI":"10.1186\/s40734-017-0051-5"},{"key":"831_CR22","doi-asserted-by":"publisher","unstructured":"Rodrigues FB, Duarte GS, Costa J, et al. Tetrabenazine versus deutetrabenazine for Huntington\u2019s disease: twins or distant cousins? Mov Disord Clin Pract. 2017;4(4)582\u201385. doi: 10.1002\/mdc3.12483","DOI":"10.1002\/mdc3.12483"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0831-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0831-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0831-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T22:59:14Z","timestamp":1719529154000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0831-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,27]]},"references-count":22,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["831"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0831-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,27]]}}}